Dr. Alla Keyzner, MD

Dr. Keyzner practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Keyzner's NPI, 1801054580, was assigned on May 29, 2008. Dr. Keyzner graduated from Drexel University College of Medicine/Hahnemann University in 2003. Dr. Keyzner holds New York license 234079.

Dr. Keyzner's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Keyzner also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Keyzner's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Keyzner to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Keyzner practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Keyzner's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Keyzner is licensed in New York.

CMS data shows 459 Medicare services from Dr. Keyzner across 4 procedure codes in 2024, for 89 Medicare patients. Medicare paid $49,031 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 89 Medicare patients who saw Dr. Keyzner in 2024. The largest group is 65 to 74, with 63 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Keyzner's median patient age at 65, with 43% women.

In 2024, Dr. Keyzner wrote 1,338 Medicare Part D claims for 57 patients. 79% of them were for generic drugs. CMS names the drug for 1,127 of them, across 28 drugs with 11 or more claims each, at $2,529,349 in total drug cost. In 2023, CMS named 701 claims across 22 drugs.

Dr. Keyzner accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 26 papers to Dr. Keyzner, published from 2013 to 2024. 2020 was the busiest year, with 8. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Leukemia, Myeloid, Acute. Dr. Keyzner has published most often in Am J Hematol. Dr. Keyzner's most frequent co-authors are John O. Mascarenhas, MD, Marina Kremyanskaya, MD and Uroosa Ibrahim, MBBS.

Dmand AI links Dr. Keyzner to 3 clinical trials. Conditions studied include Anemia, Sickle Cell, Hematologic Neoplasms and Leukemia, Biphenotypic, Acute.

CMS Open Payments shows 25 general payments to Dr. Keyzner from 10 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 88% of the total. Sanofi and Genzyme US Companies paid the most, $7,463.

Dr. Keyzner graduated from Drexel University College of Medicine/Hahnemann University in 2003.